Systemic therapy for advanced pancreatic cancer

References

• Jemal A, Thomas A, Murray T, Thun M.Cancer statistics, 2002. CA Cancer IClin. 52(1), 23–47 (2002).
   Google Scholar
• Evans DB, Abbruzzese JL, Willett CG. Cancer of the pancreas. In: Principles and Practice of Oncology (6th Edition) Devita VT, Hellman S, Rosenberg SA (Eds), Lippincott-Raven, Philadelphia, PA, USA, 1126–1162 (1999).
   Google Scholar
• Geer RJ, Brennan ME. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am. J. SLIT 165, 68–73 (1993).
   Google Scholar
• Smalley SR, Macdonald JS. Pancreatic cancer. In: Medical Oncology (2nd Edition) Calabres P, Schein PS (Eds), Mcgraw Hill: New York, NY, USA, 691–712 (1999).
   Google Scholar
• Cullinan SA, Moertel CG, Fleming TR et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. Ruorouracil vs. fluorouracil and doxorubicin vs. fluorouracil, doxorubicin and mitomycin. JAIVIA 253(14), 2061-2067 (1985).
   Google Scholar
• Burris HA, Moore MJ, Andersen J et al Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. Jan. Oncol 15(6), 2403–2413 (1997).
   Google Scholar
• ••A Phase III study demonstratingsuperiority of gemcitabine over iv. bolus 5-FU in advanced pancreatic cancer.
   Google Scholar
• Touroutoglou N, Gravel D, Raber MN, Plunkett W Abbruzzese JL. Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors. Ann. Oncol 9(9), 1003–1008 (1998).
   Google Scholar
• •A novel dosing schedule of gemcitabine by fixed dose infusion.
   Google Scholar
• Casper ES, Green MR, Kasen DP et al Phase II trial of gemcitabine (2,2 difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs12(1), 29–34 (1994).
   Google Scholar
• Carmichael J, Fink U, Russell RC et al Phase II study of gemcitabine in patients with advanced pancreatic cancer. BE J. Cancer73(1), 101–105 (1996).
   Google Scholar
• Rothenberg ML, Moore MJ, Cripps MC et al A Phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann. Oncol 7 (4), 347–353 (1996).
   Google Scholar
• Temper° M, Plunkett W Ruiz van Haperen V et al Randomized Phase II trail of dose intense gemcitabine by standard infusion vs. fixed dose rate in metastatic pancreatic Adenocarcinoma. Roc Ann. Meet. Am Sac Clin. Onto]. Atlanta, GA, USA, (1999) (Abstract 1048).
   Google Scholar
• Cartwright TH, Cohn A, Varkey JA et al Phase II study of oral capecitabine in patients with advanced pancreatic cancer. J. Clin. Oncol 20(1), 160–164 (2002).
   Google Scholar
• Wagener DJ, Verdonk HE, Dirix LY et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study. Ann. Oncol 6(2), 129–132 (1995).
   Google Scholar
• Stehlin JS, Giovanella BC, Natelson EA et al A study of 9-nitrocamptothecin (RFS-20000) in patients with advanced pancreatic cancer. Int. J. Om& 14(5), 821–831 (1999).
   Google Scholar
• Rivkin S, Burris H, Gerstein H et al. A Phase II study of rubitecan (9NC) in patients with refractory pancreatic cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol New Orleans, LA, USA, (2000) (Abstract 1020).
   Google Scholar
• D'Adamo D, Hammond L, Donehower R et al Final results of a Phase II study of DX-8951f (Extacen Mesylate, DX) in advanced pancreatic cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol San Francisco, CA, USA, (2001) (Abstract 532).
   Google Scholar
• Rougier P, Adenis A, Ducreux M et al. A Phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma. Eur j Cancer 36 (8), 1016–1025 (2000).
   PubMed Web of Science ®Google Scholar
• Okada S, Sokoto Y, Matsuno S et al. Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese co-operative study. Co-operative Group of Docetaxel for Pancreatic Cancer in Japan. Br. Cancer80(3–4), 438–443 (1999).
   Google Scholar
• Oster MW, Gray R, Panasci L, Perry MC. Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin and mitomycin (FAM) with 5-fluorouracil, streptozotocin and mitomycin (FSM). Cancer57 (1), 29–33 (1986).
   Google Scholar
• •Early results of combination chemotherapy in metastatic pancreatic cancer.
   Google Scholar
• Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group." Clin. Oncol 4(12), 1794–1798 (1986).
   Google Scholar
• •Early results of combination chemotherapy in metastatic pancreatic cancer.
   Google Scholar
• Rougier P, Ducreux M, Douillard JY et al. Efficacy of 5-FU+cisplatin (fup) compared to bolus 5-fu (fu) in advanced pancreatic carcinoma (apc): a randomized trial from the French Anticancer Centers Digestive Group (FNLCCDG). St. Cloud; CHU, Besancon, France. Proc Ann. Meet Am Soc Clin Om& Atlanta, GA, USA, (1999) (Abstract 1050).
   Google Scholar
• Hidalgo M, Castellano D, Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. j Clin. Om& 17(2), 585–592 (1999).
   Google Scholar
• Berlin J, Catalano P, Thomas J, Kluger J, Haller DG, Benson AB III. A Phase III study of gemcitabine in combination with 5-FU vs. gemcitabine alone in patients with advanced pancreatic carcinoma (E2297): an Eastern Co-operative Oncology Group (ECOG) trial. Proc. Ann. Meet. Am. Soc. Clin. Om& San Francisco, CA, USA, (2001) (Abstract 505).
   Google Scholar
• •A Phase RI study comparing bolus gemcitabine with or without bolus 5-FU. Both arms were equivalent.
   Google Scholar
• Plunkett W, Huang P, Searcy CE, Gandhi V. Gemcitabine: preclinical pharmacology and mechanisms of action. Sem. Oncology 23(5 Supp1.10), 3–15 (1996).
   Google Scholar
• Heinemann V, Wilke H, Mergenthaler HG et al Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann. Oncol 11(11), 1399–1403 (2000).
   PubMed Web of Science ®Google Scholar
• Philip PA, Zalupski M, Vaitkevicius VK et al Phase II study of gemcitabine and cisplatin in advanced or metastatic pancreatic cancer Cancer 3,569–577 (2001).
   Google Scholar
• Colucci G, Giuliani F, Gebbia V et al Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized Phase III study of the Gruppo Oncologia dentalia Meridionale. Cancer 94(4), 902–910 (2002).
   PubMed Web of Science ®Google Scholar
• Faivre S, Raymond E, Woynarowski JM, Cvitkovic E. Supraadditive effect of 2',2'-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines. Cancer Chemother. Pharmacol 44(2), 117–123 (1999).
   Google Scholar
• Louvet C, Andre T, Lledo G et al A. Gemcitabine combined with Oxaliplatin in advanced pancreatic adenocarcinoma : final results of a GERCOR multicenter Phase II study. J Clin Oncol 20 (6), 1512–1518 (2002).
   PubMed Web of Science ®Google Scholar
• Sherman WH, Fine RL. Combination gemcitabine and docetaxel therapy in advanced adenocarcinoma of the pancreas. Oncology60(4), 316–321 (2001).
   PubMed Web of Science ®Google Scholar
• Stathopoulos GP, Mavroudis D, Tsavaris N et al Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a Phase II study of the Greek Co-operative Group for Pancreatic Cancer. Ann. Om& 12(1), 101–103 (2001).
   Google Scholar
• Stapthopoulos G, Rigatos G, Kouroussis C et al Front-line treatment with gemcitabine in combination with Irinotecan: preliminary results of a multicenter Phase II study. Floc. Ann. Meet. Am. Soc. Clin. Oncol New Orleans, LA, USA, (2000) (Abstract 1260).
   Google Scholar
• Rocha Lima CMS, Savarese D, Bruckner H et al Irinotecan plus gemcitabine induces both radiographic and CA 19–9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. 1 Clin. Oncol 20(5), 1182–1191 (2002).
   Google Scholar
• Kindler HL, Dugan W, Hochster H, Strickland D, Jacobs A, John WJ. Clinical outcomes in patients with advanced pancreatic cancer treated with pemetrexed/ gemcitabine. Proc Ann. Meet. Am. Soc. Clin. Oncol Orlando, Fl, USA, (2002) (Abstract 499).
   Google Scholar
• Burtness B, Argiris A, Rich RS et al Weekly chemotherapy with Irinotecan plus taxanes in advanced pancreatic cancer. Proc Ann. Meet. Am. Soc. Clin. Om& New Orleans, LA, USA, (2000) (Abstract 263).
   Google Scholar
• Philip PA, Zalupski M, El-Rayes BF et al Phase II study of gemcitabine, cisplatin and infusional 5-FU in patients with metastatic pancreatic cancer. Proc Ann. Meet. Am. Soc. Clin. Oncol Orlando, F1, USA, (2002). (Abstract 499).
   Google Scholar
• Reni M, Passoni P, Pancucci MG et al Definitive results of a Phase II trial of cisplatin, epirubicin, continuous-infusion fluorouracil and gemcitabine in stage IV pancreatic adenocarcinoma. j Clin. Oncol 19(10), 2679–2686 (2001).
   Google Scholar
• Koshiba T, Hosotani R, Wada M et al Involvement of matrix met alloproteinase-2 activity in invasion and metastasis of pancreatic carcinoma. Cancer 82 (4), 642–650 (1998).
   Google Scholar
• Hag M, Shafii A, Zervos EE, Rosemurgy AS. Addition of matrix met alloproteinase inhibition to conventional cytotoxic therapy reduces tumor implantation and prolongs survival in a murine model of human pancreatic cancer. Cancer Res. 60(12), 3207–3211 (2000).
   Google Scholar
• Bramhall SR, Rosemurgy A, Brown PD, Browry C, Buckels JA. Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomized trial. Clin. Oncol 19(15), 3447–3455 (2001).
   Google Scholar
• • A Phase III trial comparing gemcitabine with marimastat. The two treatments were similar with respect to overall survival.
   Google Scholar
• Malcolm MJ, Hamm J, Eisenberg P et al. A comparison between gemcitabine ant the matrix met alloproteinase inhibitor (IVIMP) BAY 12–9566 in patients with advanced pancreatic cancer. Proc. Ann. Meet. Am. Soc. Clin. Oncol Orlando, Fl, USA (2002) (Abstract 930).
   Google Scholar
• Cao Y, Pearman AT, Zimmerman GA, McIntyre TM, Prescott SM. Intracellular unesterified arachidonic acid signals apoptosis. Proc. Nat/Acad. Sci. USA 97(21), 11280–11285 (2000).
   Google Scholar
• Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Nat/Acad. Sci USA 94(7), 3336–3340 (1997).
   Google Scholar
• Chiarugi V, Magnelli L, Gallo O. COX-2, iNOS and p53 as play-makers of tumor angiogenesis. Intern. j Mal Merl. 2 (6), 715–719 (1998).
   Google Scholar
• Tucker N, Dannenberg AJ, Yang, EK et al Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res. 59(5), 987–990, (1999).
   Google Scholar
• •Evidence of elevated cyclooxygenase-2 expression in human pancreatic cancer.
   Google Scholar
• Williams CS, Mann M, DuBois RN. The role of cyclooxygenases in inflammation, cancer and development. Oncogenes 18 (55), 7908–7916 (1999).
   PubMed Web of Science ®Google Scholar
• Molina MA, Sitja—Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 59(17), 4356–4362 (1999).
   Google Scholar
• Korc M, Chandrasekar B, Yamanaka Y, Friess H, Buchier M, Beger HG. Overexpression of the epidermal growth factor receptor in human pancreatic cancer is associated with concomitant increases in the levels of epidermal growth factor and transforming growth factor alpha. j Clin. Invest. 90,1352–1360 (1992).
   PubMed Web of Science ®Google Scholar
• •Identification of epidermal growth factor receptor as a potential target in pancreatic cancer.
   Google Scholar
• Ozawa F, Friess H, Tempia-Caliera A, Kleeff J, Bachler MW. Growth factors and their receptors in pancreatic cancer. 7eratog Carcinog Mutagen 21,27–44 (2001).
   Google Scholar
• Ymanaka Y, Friess H, Kobrin MS, Buchler M, Beger HG, Korc M. Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness. AntiCancer Res. 13,565–569 (1993).
   PubMed Web of Science ®Google Scholar
• Wagner M, Cao T, Lopez ME et al Expression of a truncated EGF receptor is associated with inhibition of pancreatic cancer cell growth and enhanced sensitivity to cisplatinum. Int. j Cancer 68,782–787 (1996).
   PubMed Web of Science ®Google Scholar
• Safran H, Steinhoff M, Mangray S et al. Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma. Am.Clin. Oncol 24 (5), 496–499 (2001).
   Google Scholar
• •Overexpression of HER-2/neu in pancreatic cancer.
   Google Scholar
• Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ. The nuclear factor-k B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin. Cancer Res. 5(1), 119–127 (1999).
   PubMedGoogle Scholar
• •Evidence of overexpression of nuclear factor-ic B in pancreatic cancer as a potential target for therapy.
   Google Scholar
• Cheng JQ, Altomare DA, Klein MA et al Transforming activity and mitosis-related expression of the AKT2 oncogene: evidence suggesting a link between cell cycle regulation and oncogenesis. Oncogene 14(23), 2793–2801 (1997).
   Google Scholar
• Sun J, Blaskovich MA, Knowles D et al Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol and gemcitabine. Cancer Res. 59(19), 4919–4926 (1999).
   Google Scholar
• Macdonald JS, Chansky K, Whitehead J, Wade J, Giguere J, Abbruzzese JL. A Phase II study of the farnesyl transferase inhibitor R115777 in pancreatic cancer. A Southwestern Oncology Group (SWOG) study. Proc. Ann. Meet. Am. Soc. Clin. Oncol Orlando, Fl, USA, (2002) (Abstract 548).
   Google Scholar
• •Demonstration of lack of benefit of a farnesyl transferase inhibitor in patients with pancreatic cancer.
   Google Scholar
• Overhosler JP, Prewett MC, Hooper AT, Waksal HW, Hicldin DJ. Epidermal growth factor receptor blockade by antibody IMC-C225 inhibits growth of a human pancreatic carcinoma xenograft in nude mice. Cancer 89,74–82 (2000).
   Google Scholar
• Bruns CJ, Harbison MT, Davis DW et al Epidermal growth factor receptor blockade with C225 plus gemcitabine results in regression of human pancreatic carcinoma growing orthotopically in nude mice by anti-angiogenic mechanisms. Clin. Cancer Res. 6(5), 1936–1948 (2000).
   Google Scholar
• Abbruzzese J, Rosenberg A, Xiong Q et al. Phase II study of anti-epidermal growth factor receptor (EGFR) antibody cetuximab (IMC-C225) in combination with gemcitabine in patients advanced pancreatic cancer. Proc. Ann. Meet. Am Soc. Clin. Oncol San Francisco, CA, USA, (2001) (Abstract 518a).
   Google Scholar
• •Clinical trial suggesting improved efficacy of gemcitabine when combined with an EGFR inhibitor (IMC-C225).
   Google Scholar
• Safran H, Ramanathan RK, Schwartz J et al. Herceptin and gemcitabine for metastatic pancreatic cancers that overexpress HER-2/neu. Proc. Ann. Meet. Am Soc. Clin. Oncol San Francisco, CA, USA, (2001) (Abstract 517).
   Google Scholar
• •Clinical trial suggesting improved efficacy of gemcitabine when combined with Herceptin in patients with HER-2/neu overexpressing pancreatic cancer.
   Google Scholar
• Nelson JM, Fry DW. Inhibition of ERBB family receptors by CI-1033 enhances the cytotoxicity of gemcitabine via modulation of akt and MAPKs. Proc. Am. Assoc. Cancer Res. San Francisco, CA, USA, (2001) (Abstract 1533).
   Google Scholar
• Ng SSW, Tsao MS, Chow S, Hedley DW. Inhibition of phosphatidylinositide 3-kinase enhances gemcitabine-induced apoptosis in human pancreatic cancer cells. Cancer Res. 60 (19), 5451–5455 (2000).
   Google Scholar
• Shah MA, Schwartz GK. Cell cycle-mediated drug resistance: an emerging concept in cancer therapy. Clin. Cancer Res. 7,2168–2181 (2001).
   PubMed Web of Science ®Google Scholar
• Jung CP, Motwani MV, Schwartz GK. Ravopiridol increases sensitization to gemcitabine in human gastrointestinal cancer cell lines and correlates with downregulation of ribonucleotide reductase M2 subunit. Clin. Cancer Res. 7,2527-2536 (2001).
   Google Scholar
• Davis S, Aldrich TH, Jones PP et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Ce//87(7),1161–1169 (1996).
   Google Scholar
• Strydom DJ, Fett JW, Riordan JE The odyssey of angiogenin: a protein that induces blood vessel growth. Anal Chem. 61(20), 1173A-1179A (1989).
   Google Scholar
• Seo Y, Baba H, Fukuda T, Takashima M, Sugimachi K. High expression of vascular endothelial growth factor is associated with liver metastasis and a poor prognosis for patients with ductal pancreatic adenocarcinoma. Cancer 88 (10), 2239–2245 (2002).
   Google Scholar
• Luo J, Guo P, Matsuda K et al Pancreatic cancer cell-derived vascular endothelial growth factor is biologically active in vitro and enhances tumorigenicity in vivo. Int.j Cancer92(3), 361–369 (2001).
   PubMed Web of Science ®Google Scholar
• Shishido T, Yasoshima T, Denno R, Mukaiya M, Sato N, Hirata K. Inhibition of liver metastasis of human pancreatic carcinoma by angiogenesis inhibitor TNP-470 in combination with cisplatin. Jpn Cancer Res. 89(9), 963–969 (1998).
   Google Scholar
• Aghajanian C, Soignet S, Dizon DS et al. A Phase I trial of the novel proteasome inhibitor PS341 in advanced solid tumor malignancies. Proc. Ann. Meet. Am. Soc. Clin. Oncol San Francisco, CA, USA, (2001) (Abstract 338).
   Google Scholar
• LoRusso PM, Demchik L, Foster B et al Preclinical antitumor activity of CI-994. Invest New Drugs 14(4), 349–356 (1996).
   Google Scholar
• Richards DA, Waterhouse DM, Wagener DJ et al Randomized, double-blinded, placebo control Phase 2 study of the histone deacetylase inhibitor CI-994 plus gemcitabine versus placebo plus gemcitabine in the treatment of patients with advanced pancreatic cancer. Proc Ann. Meet Am Soc Clin Oncol Orlando, Fl, USA, (2002) (Abstract 644).
   Google Scholar
• Kelner MJ, Tsigelny I, Sharikov V, Ten Eyck LF, Elayadi AN, McMorris TC. Phage display panning of irofulven identifies potential intracellular targets. Proc. Amer Assoc. Cancer Res. San Francisco, CA, USA, (2001) (Abstract 220).
   Google Scholar
• Wang W, Water SJ, MacDonald JR et al. Irofluven-induced apoptosis in human pancreatic cancer cells is mediated by ERK and JNK kinases. Anticancer Res. 22(2A), 559–564 (2002).
   Google Scholar
• Thomas JP, Arzomanian R, Alberti D et al Phase I clinical and Pharmacokinetic trials of irofulven. Cancer Chemother Phatmacol 48(6), 467–472 (2001).
   PubMedGoogle Scholar
• Weitman SD, Smith S, Eder JP et al. Irofulven monotherapy: impressive Phase I and II clinical antitumor activity in heavily treated patients. Proc. Ann. Meet. Am. Soc. Clin. Oncol San Francisco, CA, USA, (2001) (Abstract 2081).
   Google Scholar
• Pegg AE. Polyamine metabolism and its importance in neoplastic growth and as a target for chemotherapy. Cancer Res. 48, 759–774 (1988).
   PubMed Web of Science ®Google Scholar
• Esken FA, Greim GA, van Zuylen C et al. Phase I and Pharmacological study of weekly adminstration of the polyamine synthesis inhibitor SAM 486A (CGP 48 664) in patients with solid tumors. Clin. Cancer Res. 6,1736-1743 (2000).
   Google Scholar